Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc. is a developmental-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative botanical drugs. The company's mission is to address significant unmet medical needs and improve patients' lives by leveraging natural substances, primarily focusing on inflammatory diseases. Its principal executive offices are located in Jericho, New York.

Curanex's lead product candidate is Phyto-N, a proprietary botanical extract with anti-inflammatory properties derived from a single medicinal plant. Phyto-N is currently in preclinical development, targeting various therapeutic areas including ulcerative colitis (its primary focus), atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), gout, and cancer cachexia. The company aims to develop therapies for immune and inflammatory diseases, metabolic diseases, and viral infections.

Led by CEO Jun Liu, Curanex Pharmaceuticals completed its initial public offering (IPO) on the Nasdaq Capital Market in August 2025, trading under the ticker symbol CURX. The company is actively advancing Phyto-N towards an Investigational New Drug (IND) submission for ulcerative colitis in the fourth quarter of 2026, with plans to initiate Phase 1 clinical development in Australia. As a developmental-stage company, Curanex currently has no commercial products and relies on future financing to fund its ongoing operations.